

Thomas Eschenhagen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8018923/publications.pdf>

Version: 2024-02-01

124
papers

10,208
citations

53660

45
h-index

35952

97
g-index

128
all docs

128
docs citations

128
times ranked

10171
citing authors

#	ARTICLE	IF	CITATIONS
1	Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts. <i>Nature Medicine</i> , 2006, 12, 452-458.	15.2	928
2	What Is the Role of β^2 -Adrenergic Signaling in Heart Failure?. <i>Circulation Research</i> , 2003, 93, 896-906.	2.0	687
3	Three-dimensional reconstitution of embryonic cardiomyocytes in a collagen matrix: a new heart muscle model system. <i>FASEB Journal</i> , 1997, 11, 683-694.	0.2	584
4	Development of a Drug Screening Platform Based on Engineered Heart Tissue. <i>Circulation Research</i> , 2010, 107, 35-44.	2.0	420
5	Cardiomyocyte Regeneration. <i>Circulation</i> , 2017, 136, 680-686.	1.6	417
6	Chronic stretch of engineered heart tissue induces hypertrophy and functional improvement. <i>FASEB Journal</i> , 2000, 14, 669-679.	0.2	371
7	Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2011, 13, 1-10.	2.9	350
8	Human Engineered Heart Tissue as a Versatile Tool in Basic Research and Preclinical Toxicology. <i>PLoS ONE</i> , 2011, 6, e26397.	1.1	305
9	Functional improvement and maturation of rat and human engineered heart tissue by chronic electrical stimulation. <i>Journal of Molecular and Cellular Cardiology</i> , 2014, 74, 151-161.	0.9	305
10	Human Engineered Heart Tissue: Analysis of Contractile Force. <i>Stem Cell Reports</i> , 2016, 7, 29-42.	2.3	292
11	Three-Dimensional Human iPSC-Derived Artificial Skeletal Muscles Model Muscular Dystrophies and Enable Multilineage Tissue Engineering. <i>Cell Reports</i> , 2018, 23, 899-908.	2.9	245
12	MUSCLEMOTION. <i>Circulation Research</i> , 2018, 122, e5-e16.	2.0	235
13	Cardiac repair in guinea pigs with human engineered heart tissue from induced pluripotent stem cells. <i>Science Translational Medicine</i> , 2016, 8, 363ra148.	5.8	215
14	Position Paper of the European Society of Cardiology Working Group Cellular Biology of the Heart: cell-based therapies for myocardial repair and regeneration in ischemic heart disease and heart failure. <i>European Heart Journal</i> , 2016, 37, 1789-1798.	1.0	210
15	Engineering Cardiac Muscle Tissue. <i>Circulation Research</i> , 2017, 120, 1487-1500.	2.0	202
16	Metabolic Maturation Media Improve Physiological Function of Human iPSC-Derived Cardiomyocytes. <i>Cell Reports</i> , 2020, 32, 107925.	2.9	198
17	Differentiation of cardiomyocytes and generation of human engineered heart tissue. <i>Nature Protocols</i> , 2017, 12, 1177-1197.	5.5	197
18	SARS-CoV-2 infects and induces cytotoxic effects in human cardiomyocytes. <i>Cardiovascular Research</i> , 2020, 116, 2207-2215.	1.8	189

#	ARTICLE	IF	CITATIONS
19	CRISPR/Cas9 editing in human pluripotent stem cell-cardiomyocytes highlights arrhythmias, hypocontractility, and energy depletion as potential therapeutic targets for hypertrophic cardiomyopathy. <i>European Heart Journal</i> , 2018, 39, 3879-3892.	1.0	176
20	Contractile Work Contributes to Maturation of Energy Metabolism in hiPSC-Derived Cardiomyocytes. <i>Stem Cell Reports</i> , 2018, 10, 834-847.	2.3	148
21	Human engineered heart tissue as a model system for drug testing. <i>Advanced Drug Delivery Reviews</i> , 2016, 96, 214-224.	6.6	146
22	Human iPSC-derived cardiomyocytes cultured in 3D engineered heart tissue show physiological upstroke velocity and sodium current density. <i>Scientific Reports</i> , 2017, 7, 5464.	1.6	140
23	Atrial-like Engineered Heart Tissue: An In Vitro Model of the Human Atrium. <i>Stem Cell Reports</i> , 2018, 11, 1378-1390.	2.3	132
24	Increased afterload induces pathological cardiac hypertrophy: a new in vitro model. <i>Basic Research in Cardiology</i> , 2012, 107, 307.	2.5	131
25	Mybpc3 gene therapy for neonatal cardiomyopathy enables long-term disease prevention in mice. <i>Nature Communications</i> , 2014, 5, 5515.	5.8	131
26	Increased myofilament Ca ²⁺ sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in mice. <i>Journal of Molecular and Cellular Cardiology</i> , 2012, 52, 1299-1307.	0.9	118
27	Low Resting Membrane Potential and Low Inward Rectifier Potassium Currents Are Not Inherent Features of hiPSC-Derived Cardiomyocytes. <i>Stem Cell Reports</i> , 2018, 10, 822-833.	2.3	92
28	Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the <scp>Translational Research Committee</scp> of the <scp>Heart Failure Association</scp> (<scp>HFA</scp>) of the <scp>European Society of Cardiology</scp> (<scp>ESC</scp>). <i>European Journal of Heart Failure</i> , 2020, 22, 2272-2289.	2.9	92
29	Disease modeling of a mutation in α -actinin 2 guides clinical therapy in hypertrophic cardiomyopathy. <i>EMBO Molecular Medicine</i> , 2019, 11, e11115.	3.3	88
30	Long Noncoding RNA-Enriched Vesicles Secreted by Hypoxic Cardiomyocytes Drive Cardiac Fibrosis. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 18, 363-374.	2.3	83
31	Targeting muscle-enriched long non-coding RNA <i>H19</i> reverses pathological cardiac hypertrophy. <i>European Heart Journal</i> , 2020, 41, 3462-3474.	1.0	81
32	Dichloroacetate prevents restenosis in preclinical animal models of vessel injury. <i>Nature</i> , 2014, 509, 641-644.	13.7	78
33	Evaluation of MYBPC3 trans -Splicing and Gene Replacement as Therapeutic Options in Human iPSC-Derived Cardiomyocytes. <i>Molecular Therapy - Nucleic Acids</i> , 2017, 7, 475-486.	2.3	74
34	Human Engineered Heart Tissue Patches Remuscularize the Injured Heart in a Dose-Dependent Manner. <i>Circulation</i> , 2021, 143, 1991-2006.	1.6	73
35	Towards standardization of echocardiography for the evaluation of left ventricular function in adult rodents: a position paper of the ESC Working Group on Myocardial Function. <i>Cardiovascular Research</i> , 2021, 117, 43-59.	1.8	72
36	Cardiac arrhythmia induced by genetic silencing of hKv4.3 channels is rescued by GIRK4 inactivation. <i>Nature Communications</i> , 2014, 5, 4664.	5.8	70

#	ARTICLE	IF	CITATIONS
37	Human Induced Pluripotent Stem Cellâ€œDerived Engineered Heart Tissue as a Sensitive Test System for QT Prolongation and Arrhythmic Triggers. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2018, 11, e006035.	2.1	70
38	Automated analysis of contractile force and Ca ²⁺ transients in engineered heart tissue. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2014, 306, H1353-H1363.	1.5	69
39	Aging-regulated anti-apoptotic long non-coding RNA Sarrah augments recovery from acute myocardial infarction. <i>Nature Communications</i> , 2020, 11, 2039.	5.8	63
40	Repair of Mybpc3 mRNA by 5â€²-trans-splicing in a Mouse Model of Hypertrophic Cardiomyopathy. <i>Molecular Therapy - Nucleic Acids</i> , 2013, 2, e102.	2.3	61
41	Cardiomyopathy phenotypes in human-induced pluripotent stem cell-derived cardiomyocytesâ€œa systematic review. <i>Pflugers Archiv European Journal of Physiology</i> , 2019, 471, 755-768.	1.3	57
42	In-vitro perfusion of engineered heart tissue through endothelialized channels. <i>Tissue Engineering - Part A</i> , 2014, 20, 131025032956001.	1.6	52
43	Blinded Contractility Analysis in hiPSC-Cardiomyocytes in Engineered Heart Tissue Format: Comparison With Human Atrial Trabeculae. <i>Toxicological Sciences</i> , 2017, 158, 164-175.	1.4	52
44	Simultaneous measurement of excitation-contraction coupling parameters identifies mechanisms underlying contractile responses of hiPSC-derived cardiomyocytes. <i>Nature Communications</i> , 2019, 10, 4325.	5.8	51
45	Blinded, Multicenter Evaluation of Drug-induced Changes in Contractility Using Human-induced Pluripotent Stem Cell-derived Cardiomyocytes. <i>Toxicological Sciences</i> , 2020, 176, 103-123.	1.4	51
46	Comparison of the effects of a truncating and a missense MYBPC3 mutation on contractile parameters of engineered heart tissue. <i>Journal of Molecular and Cellular Cardiology</i> , 2016, 97, 82-92.	0.9	48
47	Ca ²⁺ -Currents in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Effects of Two Different Culture Conditions. <i>Frontiers in Pharmacology</i> , 2016, 7, 300.	1.6	47
48	Comparison of 10 Control hPSC Lines for Drug Screening in an Engineered Heart Tissue Format. <i>Stem Cell Reports</i> , 2020, 15, 983-998.	2.3	45
49	Human pluripotent stem cell-derived cardiomyocytes for studying energy metabolism. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2020, 1867, 118471.	1.9	43
50	Pharmacological inhibition of DNA methylation attenuates pressure overload-induced cardiac hypertrophy in rats. <i>Journal of Molecular and Cellular Cardiology</i> , 2018, 120, 53-63.	0.9	42
51	Deciphering the microRNA signature of pathological cardiac hypertrophy by engineered heart tissue- and sequencing-technology. <i>Journal of Molecular and Cellular Cardiology</i> , 2015, 81, 1-9.	0.9	41
52	Force and Calcium Transients Analysis in Human Engineered Heart Tissues Reveals Positive Force-Frequency Relation at Physiological Frequency. <i>Stem Cell Reports</i> , 2020, 14, 312-324.	2.3	40
53	â€œGlutathiolation impairs phosphoregulation and function of cardiac myosinâ€œbinding protein C in human heart failure. <i>FASEB Journal</i> , 2016, 30, 1849-1864.	0.2	38
54	Ranolazine antagonizes catecholamine-induced dysfunction in isolated cardiomyocytes, but lacks long-term therapeutic effects in vivo in a mouse model of hypertrophic cardiomyopathy. <i>Cardiovascular Research</i> , 2016, 109, 90-102.	1.8	38

#	ARTICLE	IF	CITATIONS
55	Chronic intermittent tachypacing by an optogenetic approach induces arrhythmia vulnerability in human engineered heart tissue. <i>Cardiovascular Research</i> , 2020, 116, 1487-1499.	1.8	38
56	An Important Role for DNMT3A-Mediated DNA Methylation in Cardiomyocyte Metabolism and Contractility. <i>Circulation</i> , 2020, 142, 1562-1578.	1.6	38
57	Analysis of Tyrosine Kinase Inhibitor-Mediated Decline in Contractile Force in Rat Engineered Heart Tissue. <i>PLoS ONE</i> , 2016, 11, e0145937.	1.1	36
58	The E3 ubiquitin ligase Asb2 ¹² is downregulated in a mouse model of hypertrophic cardiomyopathy and targets desmin for proteasomal degradation. <i>Journal of Molecular and Cellular Cardiology</i> , 2015, 87, 214-224.	0.9	35
59	Rat atrial engineered heart tissue: a new in vitro model to study atrial biology. <i>Basic Research in Cardiology</i> , 2018, 113, 41.	2.5	34
60	Impairment of the ER/mitochondria compartment in human cardiomyocytes with PLN p.Arg14del mutation. <i>EMBO Molecular Medicine</i> , 2021, 13, e13074.	3.3	34
61	PPARdelta activation induces metabolic and contractile maturation of human pluripotent stem cell-derived cardiomyocytes. <i>Cell Stem Cell</i> , 2022, 29, 559-576.e7.	5.2	34
62	General practitioners' adherence to chronic heart failure guidelines regarding medication: the GP-HF study. <i>Clinical Research in Cardiology</i> , 2016, 105, 441-450.	1.5	32
63	Effects of proarrhythmic drugs on relaxation time and beating pattern in rat engineered heart tissue. <i>Basic Research in Cardiology</i> , 2014, 109, 436.	2.5	30
64	Animal models and animal-free innovations for cardiovascular research: current status and routes to be explored. Consensus document of the ESC Working Group on Myocardial Function and the ESC Working Group on Cellular Biology of the Heart. <i>Cardiovascular Research</i> , 2022, 118, 3016-3051.	1.8	30
65	Guanabenz Interferes with ER Stress and Exerts Protective Effects in Cardiac Myocytes. <i>PLoS ONE</i> , 2014, 9, e98893.	1.1	29
66	Generation of Strip-Format Fibrin-Based Engineered Heart Tissue (EHT). <i>Methods in Molecular Biology</i> , 2014, 1181, 121-129.	0.4	29
67	Human iPS cell-derived engineered heart tissue does not affect ventricular arrhythmias in a guinea pig cryo-injury model. <i>Scientific Reports</i> , 2019, 9, 9831.	1.6	28
68	Cardiac Regeneration: New Hope for an Old Dream. <i>Annual Review of Physiology</i> , 2021, 83, 59-81.	5.6	28
69	DNA methylation in an engineered heart tissue model of cardiac hypertrophy: common signatures and effects of DNA methylation inhibitors. <i>Basic Research in Cardiology</i> , 2016, 111, 9.	2.5	27
70	Heart regeneration. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2016, 1863, 1749-1759.	1.9	25
71	In vivo grafting of large engineered heart tissue patches for cardiac repair. <i>JCI Insight</i> , 2021, 6, .	2.3	23
72	Piezo-bending actuators for isometric or auxotonic contraction analysis of engineered heart tissue. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , 2019, 13, 3-11.	1.3	22

#	ARTICLE	IF	CITATIONS
73	Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC). <i>European Journal of Heart Failure</i> , 2022, 24, 406-420.	2.9	22
74	Prominent differences in left ventricular performance and myocardial properties between right ventricular and left ventricular-based pacing modes in rats. <i>Scientific Reports</i> , 2017, 7, 5931.	1.6	21
75	Spontaneous Formation of Extensive Vessel-Like Structures in Murine Engineered Heart Tissue. <i>Tissue Engineering - Part A</i> , 2016, 22, 326-335.	1.6	19
76	Pharmacokinetics of the Experimental Non-Nucleosidic DNA Methyl Transferase Inhibitor <i>N</i> -Phthalyl-L-tryptophan (RG108) in Rats. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2016, 118, 327-332.	1.2	16
77	Translational investigation of electrophysiology in hypertrophic cardiomyopathy. <i>Journal of Molecular and Cellular Cardiology</i> , 2021, 157, 77-89.	0.9	16
78	Characterization of the PLN p.Arg14del Mutation in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13500.	1.8	16
79	LQT1-phenotypes in hiPSC: Are we measuring the right thing?. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E1968.	3.3	15
80	Exogenous Nitric Oxide Protects Human Embryonic Stem Cell-Derived Cardiomyocytes against Ischemia/Reperfusion Injury. <i>Oxidative Medicine and Cellular Longevity</i> , 2016, 2016, 1-9.	1.9	15
81	Myocardial tissue engineering for cardiac repair. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 294-298.	0.3	15
82	Magnetics-Based Approach for Fine-Tuning Afterload in Engineered Heart Tissues. <i>ACS Biomaterials Science and Engineering</i> , 2019, 5, 3663-3675.	2.6	15
83	Towards a Tissue-Engineered Contractile Fontan-Conduit: The Fate of Cardiac Myocytes in the Subpulmonary Circulation. <i>PLoS ONE</i> , 2016, 11, e0166963.	1.1	15
84	How to repair a broken heart with pluripotent stem cell-derived cardiomyocytes. <i>Journal of Molecular and Cellular Cardiology</i> , 2022, 163, 106-117.	0.9	14
85	Block of Na ⁺ /Ca ²⁺ exchanger by SEA0400 in human right atrial preparations from patients in sinus rhythm and in atrial fibrillation. <i>European Journal of Pharmacology</i> , 2016, 788, 286-293.	1.7	13
86	Implantation of hiPSC-derived Cardiac-muscle Patches after Myocardial Injury in a Guinea Pig Model. <i>Journal of Visualized Experiments</i> , 2019, , .	0.2	13
87	Phosphomimetic cardiac myosin-binding protein C partially rescues a cardiomyopathy phenotype in murine engineered heart tissue. <i>Scientific Reports</i> , 2019, 9, 18152.	1.6	13
88	Human engineered heart tissue transplantation in a guinea pig chronic injury model. <i>Journal of Molecular and Cellular Cardiology</i> , 2022, 166, 1-10.	0.9	12
89	Toward Second-Generation Cardiomyogenic and Anti-cardiofibrotic 1,4-Dihydropyridine-Class TGF β Inhibitors. <i>ChemMedChem</i> , 2019, 14, 810-822.	1.6	11
90	Impact of phosphodiesterases PDE3 and PDE4 on 5-hydroxytryptamine receptor4-mediated increase of cAMP in human atrial fibrillation. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2021, 394, 291-298.	1.4	11

#	ARTICLE	IF	CITATIONS
91	Are atrial human pluripotent stem cell-derived cardiomyocytes ready to identify drugs that beat atrial fibrillation?. <i>Nature Communications</i> , 2021, 12, 1725.	5.8	11
92	Sulforaphane exposure impairs contractility and mitochondrial function in three-dimensional engineered heart tissue. <i>Redox Biology</i> , 2021, 41, 101951.	3.9	11
93	Intermittent Optogenetic Tachypacing of Atrial Engineered Heart Tissue Induces Only Limited Electrical Remodelling. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 77, 291-299.	0.8	11
94	Comprehensive analyses of the inotropic compound omecamtiv mecarbil in rat and human cardiac preparations. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2022, 322, H373-H385.	1.5	11
95	Immunobiology of Fibrin-Based Engineered Heart Tissue. <i>Stem Cells Translational Medicine</i> , 2015, 4, 625-631.	1.6	10
96	Akrinor™, a Cafedrine/ Theodrenaline Mixture (20:1), Increases Force of Contraction of Human Atrial Myocardium But Does Not Constrict Internal Mammary Artery In Vitro. <i>Frontiers in Pharmacology</i> , 2017, 8, 272.	1.6	10
97	Heart Repair With Myocytes. <i>Circulation Research</i> , 2019, 124, 843-845.	2.0	10
98	Cell Banking of hiPSCs: A Practical Guide to Cryopreservation and Quality Control in Basic Research. <i>Current Protocols in Stem Cell Biology</i> , 2020, 55, e127.	3.0	10
99	Regulation of I _{Ca,L} and force by PDEs in human-induced pluripotent stem cell-derived cardiomyocytes. <i>British Journal of Pharmacology</i> , 2020, 177, 3036-3045.	2.7	10
100	Case Report on: Very Early Afterdepolarizations in HiPSC-Cardiomyocytes – An Artifact by Big Conductance Calcium Activated Potassium Current (I _{bc,Ca}). <i>Cells</i> , 2020, 9, 253.	1.8	10
101	A new concept of fibroblast dynamics in post-myocardial infarction remodeling. <i>Journal of Clinical Investigation</i> , 2018, 128, 1731-1733.	3.9	10
102	Incomplete Assembly of the Dystrophin-Associated Protein Complex in 2D and 3D-Cultured Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 737840.	1.8	10
103	Clonal dynamics studied in cultured induced pluripotent stem cells reveal major growth imbalances within a few weeks. <i>Stem Cell Research and Therapy</i> , 2018, 9, 165.	2.4	8
104	Normalization of force to muscle cross-sectional area: A helpful attempt to reduce data scattering in contractility studies?. <i>Acta Physiologica</i> , 2018, 224, e13202.	1.8	7
105	Blockade of miR-140-3p prevents functional deterioration in afterload-enhanced engineered heart tissue. <i>Scientific Reports</i> , 2019, 9, 11494.	1.6	7
106	Statins Do More Than Lower Cholesterol – Depending on What You Eat?. <i>Circulation</i> , 2021, 143, 1793-1796.	1.6	6
107	Prolonged action potentials in HCM-derived iPSC - biology or artefact?. <i>Cardiovascular Research</i> , 2015, 106, 6-6.	1.8	5
108	Assessment of DNA synthesis in Islet-1+ cells in the adult murine heart. <i>Biochemical and Biophysical Research Communications</i> , 2015, 456, 294-297.	1.0	5

#	ARTICLE	IF	CITATIONS
109	Mechanistic role of the CREB-regulated transcription coactivator 1 in cardiac hypertrophy. <i>Journal of Molecular and Cellular Cardiology</i> , 2019, 127, 31-43.	0.9	5
110	No impact of sex and age on beta-adrenoceptor-mediated inotropy in human right atrial trabeculae. <i>Acta Physiologica</i> , 2021, 231, e13564.	1.8	5
111	Angiotensin II receptor blocker intake associates with reduced markers of inflammatory activation and decreased mortality in patients with cardiovascular comorbidities and COVID-19 disease. <i>PLoS ONE</i> , 2021, 16, e0258684.	1.1	5
112	Regulation of basal and norepinephrine-induced cAMP and ICa in hiPSC-cardiomyocytes: Effects of culture conditions and comparison to adult human atrial cardiomyocytes. <i>Cellular Signalling</i> , 2021, 82, 109970.	1.7	4
113	I-1-deficiency negatively impacts survival in a cardiomyopathy mouse model. <i>IJC Heart and Vasculature</i> , 2015, 8, 87-94.	0.6	3
114	Hypertrophic signaling compensates for contractile and metabolic consequences of DNA methyltransferase 3A loss in human cardiomyocytes. <i>Journal of Molecular and Cellular Cardiology</i> , 2021, 154, 115-123.	0.9	3
115	A potential future Fontan modification: preliminary <i>in vitro</i> data of a pressure-generating tube from engineered heart tissue. <i>European Journal of Cardio-thoracic Surgery</i> , 2022, 62, .	0.6	3
116	Blunted beta-adrenoceptor-mediated inotropy in valvular cardiomyopathy: another piece of the puzzle in human aortic valve disease. <i>European Journal of Cardio-thoracic Surgery</i> , 2021, 60, 56-63.	0.6	2
117	No effect of thymosin beta4 on the expression of the transcription factor Islet1 in the adult murine heart. <i>Pharmacology Research and Perspectives</i> , 2018, 6, e00407.	1.1	1
118	Generation of bi-allelic MYBPC3 truncating mutant and isogenic control from an iPSC line of a patient with hypertrophic cardiomyopathy. <i>Stem Cell Research</i> , 2021, 55, 102489.	0.3	1
119	Recapitulation of dyssynchrony-associated contractile impairment in asymmetrically paced engineered heart tissue. <i>Journal of Molecular and Cellular Cardiology</i> , 2022, 163, 97-105.	0.9	1
120	Piezo2 is not an indispensable mechanosensor in murine cardiomyocytes. <i>Scientific Reports</i> , 2022, 12, 8193.	1.6	1
121	Human-Engineered Atrial Tissue for Studying Atrial Fibrillation. <i>Methods in Molecular Biology</i> , 2022, , 159-173.	0.4	1
122	Engineering Cardiovascular Regeneration. <i>Current Stem Cell Reports</i> , 2015, 1, 67-78.	0.7	0
123	Magnetic Adjustment of Afterload in Engineered Heart Tissues. <i>Journal of Visualized Experiments</i> , 2020, , .	0.2	0
124	SERCA2a gain of function in patient-derived R14Del hiPSC-CMs. <i>Journal of General Physiology</i> , 2022, 154, .	0.9	0